AVII Sarepta Therapeutics, Inc. (MM)

MicroStockProfit.com announces an investment report featuring AVI BioPharma Inc. (Nasdaq:AVII). The report includes financial, comparative and investment analyses and recent company news that you need to know to make an educated investment decision.

Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.

The full report is available at: http://www.microstockprofit.com/lp/AVII

AVII's recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, AVII is trading above its upper Bollinger Band. Relative to recent price action, the stock is currently overextended and due for either a pause or retracement.

AVI BioPharma Inc. (AVII) is a biopharmaceutical company specializing in the discovery and development of ribonucleic acid (RNA)-based drugs targeting a range of diseases. The Company has developed and optimized derivatives of its antisense chemistry (phosphorodiamidate morpholino oligomers (PMOs)) that can be designed to target disease mechanisms through mechanisms of action. The applications of AVII's RNA technology platform include genetic diseases (Duchenne muscular dystrophy (DMD)), infectious diseases (Ebola and Marburg viruses), cardiovascular disease (restenosis) and other early discovery targets. Several of its antiviral programs, including Ebola, Marburg, Junin and Dengue, have been or are funded by the U.S. government, and other governmental and non-governmental funding. On March 20, 2008, the Company acquired Ercole Biotechnology Inc.

Message Board Search for AVII: http://www.boardcentral.com/boards/AVII

In the report, the analyst notes:

"Revenues for the first quarter of 2010 were $1.2 million, down from $3.1 million in the first quarter of 2009, reflecting a decrease in government research contracts revenues of $1.9 million. The net loss for the first quarter of 2010 was $0.6 million, or $0.01 per share, compared with a net loss for the first quarter of 2009 of $0.9 million, or $0.01 per share.

"On July 14, 2010, AVII was awarded a new contract with the U.S. Department of Defense Chemical and Biological Defense Program through the U.S. Army Space and Missile Defense Command for the advanced development of the Company's hemorrhagic fever virus therapeutic candidates, AVI-6002 and AVI-6003, for Ebola and Marburg viruses, respectively."

To read the entire report visit: http://www.microstockprofit.com/lp/AVII

See what investors are saying about AVII at penny stock forum

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT:  MicroStockProfit.com
          Brian Johnson
          1-888-307-2850
          info@microstockprofit.com